For leprosy (A61P31/08)

A   Human necessities(312458)
A61P31/08                     For leprosy(15)
Antileprotic of bacteriostatic and bactericide activity relating to m. lufu, representing o-benzoylaminobenzoic acid // 2638926
FIELD: pharmacology.SUBSTANCE: invention is an o-benzoylaminobenzoic acid derivative of the following formula , which has a bacteriostatic and bactericidal activity against M. lufu.EFFECT: drug is low-toxic and has the ability to suppress the reproduction of mycobacteria.1 ex, 5 tbl

Using ep4 receptor antagonists in treating il-23-mediated diseases // 2571816
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound with EP4 receptor antagonist activity or its pharmaceutically acceptable salt, which is effective in treating an immune disease or allergy. This invention also refers to a compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt with EP4 receptor antagonist activity, which is effective in treating an immune disease or allergy. This invention also refers to a pharmaceutical composition for treating an immune disease or allergy, which contains a therapeutically effective amount of the compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt.EFFECT: invention refers to a method of treating an immune disease of allergy in an animal subject, including a mammal subject, which involves administering the compound of formula (I), (II), (III), (IV), (Va) or (Vb) or its pharmaceutically acceptable salt into the animal subject.9 cl, 3 dwg, 3 ex

Protein-free infant food // 2441399
FIELD: food industry.SUBSTANCE: this invention covers food for 0-36 month aged infants. A composition comprising free amino acids as a single source of protein, source of fat acids comprising long-chain polyunsaturated fatty acids (LCPUFA), source of carbonhydrates comprising assimilable and non-assimilable carbonhydrates and bifidus bacteria was proposed for treatment of the patients suffering from tormina, astriction, snivel, sniffle, vomit, diarrhea, feces cruentae, mucus in defecation, spots, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma, allergy for cow milk and/or intolerance to dietary protein, and/or infections. Herewith, non-assimilable carbonhydrates are chosen from milk protein-free source, and bifidus bacteria are dietary protein-free, and the whole composition is essentially intact protein-free. Besides, assimilable carbonhydrate component contains less than 2 mass percent of lactose from overall assimilable carbonhydrates. Fat component includes 0.1-5 mass percent of LCPUFA from overall fat acids content. As an alternative, this composition is applied for stimulation of immune system maturation of the infants suffering from atopic diseases.EFFECT: improvement of infant health without risks of adverse allergic reaction.25 cl, 2 dwg, 3 tbl, 1 ex

Sulphonic 2-nitro-2-(3-aryl-1,2,4-oxadiazole-5-yl)ethane derivatives exhibiting antileprotic and antituberculous activity // 2415845
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to sulphonic 2-nitro-2-(3-aryl-1,2,4-oxadiazole-5-yl)ethane derivatives of formula I a-g la R=3-NO2C6H4, R1=NO2, R2=H; b R=3-NO2C6H4, R1=NO2, R2=CH3; c R=4-CH3OC6H4, R1=NO2, R2=H; d R=4-CH3OC6H4, R1=NO2, R2=CH3; e R=4-CH3OC6H4, R1=CO2Et, R2=H; f R=4-CH3OC6H4, R1=CO2Et, R2=CH3; g R=4-CH3C6H4, R1=CO2Et, R2=H.EFFECT: preparation of the compound exhibiting antileprous and antituberculous activity.1 cl, 1 tbl, 1 ex
ethod of treating liver affection in leprosy patients // 2414895
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to leprology, and can be applied for etiopathogenetic treatment of liver affection in leprosy patients. For this purpose simultaneously with specific anti-leprous therapy introduced is hepatoprotector heptral (S-adenozyle-L-methyonine). Specific anti-leprous therapy includes course introduction of dapson in dose 100 mg daily and riphampicine in dose 600 mg 1 time per month during 6 months with following interval in 1 month. Heptral is introduced in dose 400 mg twice per day in the morning and at lunch time perorally during two weeks.EFFECT: claimed combined simultaneous introduction of medications in said regimen provides etiotropic and pathogenetic impact on disease, making it possible to realise correction of functional liver malfunctions, as well as to provide adequate protection from action of damaging factors.4 ex

Benzimidazole derivatives as selective acid pump inhibitors // 2412188
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, in which: R1, R2, R3, R4, A and E are as described in the claim, and to pharmaceutical composition containing said compounds, and a method of treating and application in order to treat conditions mediated by antagonistic activity towards acid pump, such as gastrointestinal diseases, gastrooesophageal diseases, gastrooesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcers, gastric ulcers, duodenal ulcers, NSAID- induced ulcers, gastritis, Helicobacter pylori infection, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, nonerosive reflux disease (NERD), viscerogenic pain, cancer, heartburn, nausea, oesophagitis, dysphagia, hypersalivation, disorders of the respiratory channel or asthma.EFFECT: possibility of using compounds to treat different diseases.9 cl, 1 tbl, 16 ex

ethod of obtaining extract possessing anti-leprosy activity // 2410111
FIELD: medicine.SUBSTANCE: after 6-day extraction of cultivated licorice with 40% ethanol, buffer, which contains wt % calcium chloride not more than 0.014, potassium chloride not more than 0.04, monosubstituted potassium phosphate not more than 0.006, magnesium sulphate not more than 0.02, magnesium chloride not more than 0.02, sodium chloride not more than 0.08, sodium acid carbonate not more than 0.035, sodium phosphate disubstituted not more than 0.024; glucose not more than 0.1, dissolved in 100 ml of distilled water, is added into unfiltered mixture (20 g of vegetable raw material in 100 ml of alcohol solution) in ratio 1:1 (100 ml of mixture, 100 of buffer), obtained solution is kept at temperature 3C in dark place for the following 4 days with its daily shaking. After that, solution is filtered and autoclaved three times at 0.5 atm for 10 min.EFFECT: invention allows to realise said purpose.9 tbl, 3 ex

Agent against acid-resistant microorganisms containing pyridone carboxylic acids as active component // 2299205
FIELD: organic chemistry, antibacterial agents.SUBSTANCE: invention relates to an agent used against acid-resistant microorganisms containing derivative of pyridone carboxylic acid as an active component, its pharmaceutically acceptable salt or its hydrate that elicits high antibacterial activity against Mycobacterium tuberculosis and atypical acid-resistant microorganisms. Invention describes agent used against acid-resistant microorganisms containing compound represented by the following formula (I) its salt or its hydrate as an active component wherein R1 represents cyclic alkyl group comprising 3-6 carbon atoms that can comprise substitute(s) chosen from halogen atom; R2 represents hydrogen atom; R3 represents hydrogen atom; A1 represents incomplete structure represented by the formula (2): wherein X2 represents halogen atom, alkyl group comprising 1-6 carbon atoms or alkoxy-group comprising 1-6 carbon atoms; A1, A2 and A3 form incomplete structure of the formula: in common with carbon atoms combined with them; X1 represents halogen atom; Y represents hydrogen atom; Z represents phenylpiperazine substitute. Invention provides synthesis of pyridone carboxylic acid eliciting high antibacterial activity against Mycobacterium tuberculosis and atypical acid-resistant microorganisms in combination with good pharmacokinetics indices and safety.EFFECT: valuable biological property of agent.10 cl, 9 tbl, 10 ex

Agent against acid-resistant microorganisms containing heterocyclic derivatives of benzoxazine as active component // 2297420
FIELD: chemistry of heterocyclic compounds, antibacterial agents.SUBSTANCE: invention relates to agent used against acid-resistant microorganisms. Invention describes agent against acid-resistant microorganisms containing as an active component the compound represented by the general formula (1) or its hydrate wherein R2 represents hydrogen atom; R3 represents hydrogen atom; A1, A2 and A3 form incomplete structure of the formula: wherein A1 represent incomplete structure of the formula: wherein X2 and above described R1 can be combined to form six-membered cyclic structure comprising part of the parent nucleus wherein formed ring can comprise oxygen atom and, except for, can comprise alkyl group having 1-6 carbon atoms as a substitute; X1 represents halogen atom, hydrogen atom or amino-group; Y represents hydrogen atom; Z represents incomplete structure of the formula: . Agent elicits high antibacterial activity of broad spectrum and possesses good pharmacokinetics and safety also.EFFECT: improved and valuable properties of agent.3 cl, 9 tbl, 10 ex

4,4'-sulfonyl-bis-(n,n'-dimethylammoniomethyleneaniline)-chloride, 6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-sulfonate, pharmaceutical composition based on thereof // 2275356
FIELD: organic chemistry, medicine, pharmacy.SUBSTANCE: invention relates to 4,4'-sulfonyl-bis-(N,N'-dimethylammoniomethyleneaniline)-chloride, 6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-sulfonate of the formula (I) eliciting antibacterial, antimycobacterial and immunotropic activities. Also, invention describes a pharmaceutical composition based on compound of the formula (I).EFFECT: valuable medicinal properties of compounds and composition.3 cl, 7 tbl, 2 ex

6-alkyl-5-(2-isonicotinoylsulfohydrazoyl)uracil hydrochloride and pharmaceutical composition based on thereof // 2264396
FIELD: organic chemistry, medicine, pharmacy.SUBSTANCE: invention relates to new 6-alkyl-5-(2-isonicotinoylsulfohydrazoyl)uracil hydrochlorides of the general formula (I) wherein R means alkyl comprising 1-4 carbon atom. Compounds possess an anti-mycobacterial and an immunotropic activity and can be used as an immunomodulating agent and an anti-mycobacterial agents. Also, invention relates to a pharmaceutical composition based on thereof.EFFECT: valuable medicinal properties of compounds.4 cl, 10 tbl, 2 ex

New dosage forms of demoliton in the treatment of leprosy, itching, and allergic, dermatitis herpetiformis during the // 2200550
The invention relates to the field of medicine and for new dosage forms of demoliton
 
2551132.
Up!